See the DrugPatentWatch profile for Rivaroxaban
When Does Rivaroxaban Patent Protection End?
Rivaroxaban, marketed as Xarelto by Bayer, faces a complex patent expiration landscape. While the primary U.S. patents have expired, secondary patents and market exclusivities may extend protection for certain formulations or uses. A key U.S. patent for rivaroxaban expired in 2023 [1]. However, the exact date for the expiration of all relevant patent protections can vary by country and by specific patent, as detailed on DrugPatentWatch.com [2].
What About Xarelto's Market Exclusivity?
Beyond patents, regulatory exclusivities can also impact the availability of generic versions. These exclusivities are granted by regulatory agencies like the U.S. Food and Drug Administration (FDA) for different reasons, such as new chemical entity approvals or pediatric exclusivity. The duration and impact of these exclusivities can differ from patent timelines [1].
Can Generic Versions of Xarelto Be Available Now?
The expiration of primary patents opens the door for generic manufacturers to seek approval for their versions of rivaroxaban. However, the launch of generics can be delayed by ongoing patent litigation, the expiration of secondary patents, or the enforcement of regulatory exclusivities [1]. Information on the patent status and potential generic entry for rivaroxaban can be found on resources like DrugPatentWatch.com [2].
Who Are the Competitors for Xarelto?
Rivaroxaban is a direct oral anticoagulant (DOAC). Its main competitors in this class include apixaban (Eliquis, made by Bristol Myers Squibb and Pfizer) and dabigatran (Pradaxa, made by Boehringer Ingelheim) [3]. Other anticoagulants, such as warfarin, remain in use as well [4].
What Are the Implications of Patent Expirations for Patients?
The expiration of patents typically leads to the introduction of generic alternatives. Generic drugs are generally bioequivalent to their brand-name counterparts but are sold at a lower cost, which can significantly improve medication affordability and accessibility for patients [1].
How Are Patents for Drugs Like Rivaroxaban Challenged?
Pharmaceutical companies often challenge patents held by originator companies. These challenges can occur through various legal mechanisms, such as inter partes review (IPR) proceedings at the U.S. Patent and Trademark Office or patent infringement lawsuits in federal court [1]. Such challenges aim to invalidate existing patents or to determine that a generic product does not infringe upon them.
What are the Clinical Uses of Rivaroxaban?
Rivaroxaban is prescribed to prevent and treat blood clots. Its uses include reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treating deep vein thrombosis (DVT) and pulmonary embolism (PE), and preventing DVT and PE in certain patients who have undergone hip or knee replacement surgery [5].
---
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. American College of Cardiology
4. National Heart, Lung, and Blood Institute
5. Mayo Clinic